prime medicine inc prme has set terms for its initial public offering in which the massachusettsbased biotechnology company which utilizes geneediting technology to develop therapies for a wide spectrum of diseases looks to raise up 1602 million the company said it is offering 89 million shares in the ipo which is expected to priced between 16 and 18 a share with 9434 million shares expected to be outstanding after the ipo the pricing could value the company at up to 170 billion the stock is expected to list on the nasdaq under the ticker symbol prme jp morgan goldman sachs morgan stanley and jefferies are the underwrites the company recorded a net loss of 657 million on no revenue for the six months ended june 30 after a loss of 921 million on no revenue in the same period a year ago the company is looking to go public at a time that the renaissance ipo etf ipo has tumbled 111 over the past three months while the ishares biotechnology etf ibb has slipped 23 and the sp 500 spx has declined 41